News Gilead buys in vivo cell therapy firm Interius for $350m Gilead's Kite unit has reached an agreement to buy Interius BioTherapeutics, boosting its in vivo cell therapy credentials.
Oncology CAR-T therapies: Faster, better, cheaper In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
R&D Viva in vivo: The next generation of cell therapy is fast ap... Cell therapy is a field rife with innovation, but most of the novel therapies being developed fall into one of two basic categories: autologous cell therapies, which involve removing a pati
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
